Patents by Inventor William Hansel
William Hansel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11100231Abstract: Methods, systems, and computer readable media for providing resilient computer services using systems diversity include a head device for receiving requests from clients and for replicating the requests. Variates each receive a request replicated from the head device, process the request, and generate a response to the request. At least some of the variates are different in configuration from the other. The response processing server receives the responses from the variates, selects one of the responses, and delivers the response to the client via the head device. Configuration or systems diversity and adaptation to threats and failures over time may be achieved using adaptive algorithms.Type: GrantFiled: October 10, 2016Date of Patent: August 24, 2021Inventors: Errin Wesley Fulp, Howard Donald Gage, Jr., William Hansel Turkett, Jr., David Jerome John, Daniel Alberto Canas
-
Publication number: 20180293388Abstract: Methods, systems, and computer readable media for providing resilient computer services using systems diversity include a head device for receiving requests from clients and for replicating the requests. Variates each receive a request replicated from the head device, process the request, and generate a response to the request. At least some of the variates are different in configuration from the other. The response processing server receives the responses from the variates, selects one of the responses, and delivers the response to the client via the head device. Configuration or systems diversity and adaptation to threats and failures over time may be achieved using adaptive algorithms.Type: ApplicationFiled: October 10, 2016Publication date: October 11, 2018Inventors: Errin Wesley Fulp, Howard Donald Gage, Jr., William Hansel Turkett, Jr., David Jerome John, Daniel Alberto Canas
-
Patent number: 9937260Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.Type: GrantFiled: December 21, 2015Date of Patent: April 10, 2018Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY, AGRICULTURAL AND MECHANICAL COLLEGEInventors: William Hansel, Sita Aggarwal, Robert P. Hammer
-
Publication number: 20160106853Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.Type: ApplicationFiled: December 21, 2015Publication date: April 21, 2016Inventors: William Hansel, Sita Aggarwal, Robert P. Hammer
-
Patent number: 9221877Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.Type: GrantFiled: September 16, 2009Date of Patent: December 29, 2015Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: William Hansel, Sita Aggarwal, Robert P. Hammer
-
Publication number: 20140161767Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.Type: ApplicationFiled: November 14, 2013Publication date: June 12, 2014Inventors: CAROLA LEUSCHNER, HECTOR ALILA, WILLIAM HANSEL
-
Patent number: 8258100Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: June 19, 2009Date of Patent: September 4, 2012Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20110263500Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.Type: ApplicationFiled: September 16, 2009Publication date: October 27, 2011Inventors: William Hansel, Sita Aggarwal, Robert P. Hammer
-
Publication number: 20100016227Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: June 19, 2009Publication date: January 21, 2010Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHNICAL COLLEGEInventors: FREDERICK M. ENRIGHT, JESSE M. JAYNES, WILLIAM HANSEL, KENNETH L. KOONCE, SAMUEL M. MCCANN, WEN H. YU, PATRICIA A. MELROSE, LANE D. FOIL, PHILIP H. ELZER
-
Patent number: 7566777Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: July 11, 2003Date of Patent: July 28, 2009Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20090169478Abstract: A non-invasive in vivo technique is disclosed, useful for example in detecting cancers and micrometastases. The technique may be used to selectively deliver drugs to target cells such as tumors, metastases, micrometastases, and individual malignant cells. Ligands with specificity for a target cell receptor, and optionally drug molecules as well, are covalently bound to magnetic nanoparticles, either directly or through a spacer molecule. The ligand precludes the need for a separate coating layer. For example, human breast cancer cells express receptors both for luteinizing hormone/chorionic gonadotropin (LH/CG), and for luteinizing hormone releasing hormone (LHRH). These cells can be specifically targeted by iron oxide nanoparticles covalently linked to LH/CG or LHRH. The nanoparticles are incorporated into the cancer cells through receptor-mediated endocytosis. The specific accumulation in targeted cancer cells enhances resolution for imaging, therapy, or both.Type: ApplicationFiled: August 4, 2006Publication date: July 2, 2009Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Carola Leuschner, Challa S.S.R. Kumar, William Hansel, Josef Hormes
-
Patent number: 6864086Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.Type: GrantFiled: June 14, 2002Date of Patent: March 8, 2005Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: William Hansel, Jeong-Mook Lim
-
Publication number: 20040018967Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: July 11, 2003Publication date: January 29, 2004Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 6680058Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components—the ligand and the lytic peptide—may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.Type: GrantFiled: February 22, 2000Date of Patent: January 20, 2004Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Patricia A. Melrose, Philip H. Elzer
-
Patent number: 6635740Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: September 24, 1999Date of Patent: October 21, 2003Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20030068816Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.Type: ApplicationFiled: June 14, 2002Publication date: April 10, 2003Inventors: William Hansel, Jeong-Mook Lim
-
Patent number: 6426219Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.Type: GrantFiled: May 22, 2001Date of Patent: July 30, 2002Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: William Hansel, Jeong-Mook Lim
-
Publication number: 20010034060Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.Type: ApplicationFiled: May 22, 2001Publication date: October 25, 2001Inventors: William Hansel, Jeong-Mook Lim
-
Patent number: 6255109Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.Type: GrantFiled: June 17, 1999Date of Patent: July 3, 2001Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: William Hansel, Jeong-Mook Lim